Tracer imaging in lung cancer

Hussein M. Abdel-Dayem, Andrew Scott, Homer Macapinlac, Steven Larson

Research output: Contribution to journalReview article

66 Citations (Scopus)

Abstract

Lung cancer is the leading cause of death from cancer in males. Adequate staging is essential if proper treatment is to be administered. Current morphological imaging modalities are confronted with problems in the staging of lung cancer, in the evaluation of treatment response, and in establishing whether a residual mass is due to fibrosis, residual tumors or local recurrence. Nuclear medicine imaging techniques have advanced from planar gallium-67 citrate scans in the 1970s to multihead-detector single-photon emission tomography for 67Ga, Thallium-201 chloride, technetium-99m SestaMIBI, monoclonal antibodies, and octreotide compounds. Results of positron emission tomography (PET) with fluorine-18 deoxglucose or carbon-11 methionine are very promising. PET units are now employed in centers all over the world and the recently introduced whole-body PET units will be ideal for the correct staging of malignant diseases. The current status of various nuclear medicine imaging procedures is reviewed. The problems and advantages of each scintigraphic procedure are discussed. It appears that many of the problems that confront morphological imaging will be solved by nuclear medicine techniques in the future.

Original languageEnglish (US)
Pages (from-to)57-81
Number of pages25
JournalEuropean Journal of Nuclear Medicine
Volume21
Issue number1
DOIs
StatePublished - Jan 1 1994

Fingerprint

Nuclear Medicine
Positron-Emission Tomography
Lung Neoplasms
Octreotide
Fluorine
Technetium
Residual Neoplasm
Photons
Cause of Death
Fibrosis
Monoclonal Antibodies
Tomography
Recurrence
Neoplasms

Keywords

  • Gallium-67 citrate
  • Lung cancer
  • Monoclonal antibodies
  • Positron emission tomography
  • SestaMIBI
  • Thallium-201 chloride

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Tracer imaging in lung cancer. / Abdel-Dayem, Hussein M.; Scott, Andrew; Macapinlac, Homer; Larson, Steven.

In: European Journal of Nuclear Medicine, Vol. 21, No. 1, 01.01.1994, p. 57-81.

Research output: Contribution to journalReview article

Abdel-Dayem, HM, Scott, A, Macapinlac, H & Larson, S 1994, 'Tracer imaging in lung cancer', European Journal of Nuclear Medicine, vol. 21, no. 1, pp. 57-81. https://doi.org/10.1007/BF00182307
Abdel-Dayem, Hussein M. ; Scott, Andrew ; Macapinlac, Homer ; Larson, Steven. / Tracer imaging in lung cancer. In: European Journal of Nuclear Medicine. 1994 ; Vol. 21, No. 1. pp. 57-81.
@article{12240927e87046bf97b570ae6f40a217,
title = "Tracer imaging in lung cancer",
abstract = "Lung cancer is the leading cause of death from cancer in males. Adequate staging is essential if proper treatment is to be administered. Current morphological imaging modalities are confronted with problems in the staging of lung cancer, in the evaluation of treatment response, and in establishing whether a residual mass is due to fibrosis, residual tumors or local recurrence. Nuclear medicine imaging techniques have advanced from planar gallium-67 citrate scans in the 1970s to multihead-detector single-photon emission tomography for 67Ga, Thallium-201 chloride, technetium-99m SestaMIBI, monoclonal antibodies, and octreotide compounds. Results of positron emission tomography (PET) with fluorine-18 deoxglucose or carbon-11 methionine are very promising. PET units are now employed in centers all over the world and the recently introduced whole-body PET units will be ideal for the correct staging of malignant diseases. The current status of various nuclear medicine imaging procedures is reviewed. The problems and advantages of each scintigraphic procedure are discussed. It appears that many of the problems that confront morphological imaging will be solved by nuclear medicine techniques in the future.",
keywords = "Gallium-67 citrate, Lung cancer, Monoclonal antibodies, Positron emission tomography, SestaMIBI, Thallium-201 chloride",
author = "Abdel-Dayem, {Hussein M.} and Andrew Scott and Homer Macapinlac and Steven Larson",
year = "1994",
month = "1",
day = "1",
doi = "10.1007/BF00182307",
language = "English (US)",
volume = "21",
pages = "57--81",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Tracer imaging in lung cancer

AU - Abdel-Dayem, Hussein M.

AU - Scott, Andrew

AU - Macapinlac, Homer

AU - Larson, Steven

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Lung cancer is the leading cause of death from cancer in males. Adequate staging is essential if proper treatment is to be administered. Current morphological imaging modalities are confronted with problems in the staging of lung cancer, in the evaluation of treatment response, and in establishing whether a residual mass is due to fibrosis, residual tumors or local recurrence. Nuclear medicine imaging techniques have advanced from planar gallium-67 citrate scans in the 1970s to multihead-detector single-photon emission tomography for 67Ga, Thallium-201 chloride, technetium-99m SestaMIBI, monoclonal antibodies, and octreotide compounds. Results of positron emission tomography (PET) with fluorine-18 deoxglucose or carbon-11 methionine are very promising. PET units are now employed in centers all over the world and the recently introduced whole-body PET units will be ideal for the correct staging of malignant diseases. The current status of various nuclear medicine imaging procedures is reviewed. The problems and advantages of each scintigraphic procedure are discussed. It appears that many of the problems that confront morphological imaging will be solved by nuclear medicine techniques in the future.

AB - Lung cancer is the leading cause of death from cancer in males. Adequate staging is essential if proper treatment is to be administered. Current morphological imaging modalities are confronted with problems in the staging of lung cancer, in the evaluation of treatment response, and in establishing whether a residual mass is due to fibrosis, residual tumors or local recurrence. Nuclear medicine imaging techniques have advanced from planar gallium-67 citrate scans in the 1970s to multihead-detector single-photon emission tomography for 67Ga, Thallium-201 chloride, technetium-99m SestaMIBI, monoclonal antibodies, and octreotide compounds. Results of positron emission tomography (PET) with fluorine-18 deoxglucose or carbon-11 methionine are very promising. PET units are now employed in centers all over the world and the recently introduced whole-body PET units will be ideal for the correct staging of malignant diseases. The current status of various nuclear medicine imaging procedures is reviewed. The problems and advantages of each scintigraphic procedure are discussed. It appears that many of the problems that confront morphological imaging will be solved by nuclear medicine techniques in the future.

KW - Gallium-67 citrate

KW - Lung cancer

KW - Monoclonal antibodies

KW - Positron emission tomography

KW - SestaMIBI

KW - Thallium-201 chloride

UR - http://www.scopus.com/inward/record.url?scp=0028079284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028079284&partnerID=8YFLogxK

U2 - 10.1007/BF00182307

DO - 10.1007/BF00182307

M3 - Review article

C2 - 8088287

AN - SCOPUS:0028079284

VL - 21

SP - 57

EP - 81

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 1

ER -